Chugai Pharmaceutical reported higher revenue and profit for the first half of the fiscal year ending December 2026, but its shares fell after the company left its full-year earnings forecast unchanged. Revenue rose 14.7% year on year to 663.3 billion yen, operating profit increased 16.9% to 319.6 billion yen, and interim profit grew 19.2% to 231.7 billion yen. In Japan, key products such as the ophthalmology drug Vabysmo drove growth, while overseas sales rose sharply on exports of Hemlibra to Roche and exports of an out-licensed dermatology drug. Other revenue, including royalty income, increased 44.5% to 96.8 billion yen. The stock briefly fell to the 6,800 yen level immediately after the earnings announcement, and on August 14 it closed at 6,933 yen, down about 3% from the previous day.
Chugai Pharmaceutical Co., Ltd.First-half profit rose but full-year guidance unchanged, disappointing investors.
